Skip to main content

Development of a universal influenza vaccine based on tandem core technology

Objective

FLUTCORE will develop a novel universal influenza A virus (IAV) vaccine based on the tandem core vaccine platform. Recent influenza pandemics have emphasized the urgent need for better vaccines that are reactive with multiple IAV subtypes and that are no longer dependent on intimate knowledge of the prevalent virus. We propose to replace the existing seasonal IAV vaccine with a virus like particle (VLP) carrying several invariant “universal” influenza antigens. Previous attempts to use these targets have failed due to the poor antigen expression and immunogenicity. The highly immunogenic tandem core system overcomes this limitation.
Specifically, we propose to develop a VLP carrying two or more invariant influenza antigens, express these in yeast and then examine immunogenicity in mice. The vaccine will be further tested in the rigorous ferret system before being scaled up for manufacture. An optimal clone will then be transferred to an accredited contract manufacturer for production. A phase I clinical trial will be carried out once pre-clinical toxicology has been successfully completed. Our consortium will examine the immune responses in both animals and humans thoroughly to ensure that the vaccine candidate chosen can produce a protective IAV immune response in all individuals.
To achieve these objectives, our proposal builds upon the complementary expertise of seven high-performing partners representing four European countries, with world leadership in HBV core biology, immunological analysis, commercial manufacture and influenza clinical trials, making our consortium ideally positioned to develop the vaccine and to take it from bench to bedside. The leading role of SMEs in the consortium will ensure that the technology developed by FLUTCORE will generate highly marketable products, offering both improved patient protection and long-term cost savings for health care in Europe once annual influenza vaccines are replaced.

Call for proposal

FP7-HEALTH-2013-INNOVATION-1
See other projects for this call

Funding Scheme

CP-FP - Small or medium-scale focused research project

Coordinator

UCL Elizabeth Garrett Anderson Institute for Women’s Health
Address
Gower Street
WC1E 6BT London
United Kingdom
Activity type
Higher or Secondary Education Establishments
EU contribution
€ 657 202,44
Administrative Contact
Michael Browne (Mr.)

Participants (6)

UNIVERSITY OF LEEDS
United Kingdom
EU contribution
€ 269 606,89
Address
Woodhouse Lane
LS2 9JT Leeds
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Martin Hamilton (Mr.)
LATVIJAS BIOMEDICINAS PETIJUMU UN STUDIJU CENTRS
Latvia
EU contribution
€ 315 657,27
Address
Ratsupites Iela 1
1067 Riga
Activity type
Research Organisations
Administrative Contact
Liga Vonda
IQUR LIMITED
United Kingdom
EU contribution
€ 945 758,25
Address
Royal College Street 2 London
NW1 0NH London
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Mike Whelan (Dr.)
LUXEMBOURG INSTITUTE OF HEALTH
Luxembourg
EU contribution
€ 666 407,59
Address
Val Fleuri 84
1526 Luxembourg
Activity type
Research Organisations
Administrative Contact
Thomas Lentz (Mr.)
3P BIOPHARMACEUTICALS SL
Spain
EU contribution
€ 289 082,77
Address
Calle Mocholi 2 Poligono Mocholi
31110 Noain Navarra
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Barbara Fernandez De Manzanos (Ms.)
INSTITUT CATALA DE LA SALUT
Spain
EU contribution
€ 18 588,45
Address
Gran Via De Les Corts Catalanes 587
08007 Barcelona
Activity type
Public bodies (excluding Research Organisations and Secondary or Higher Education Establishments)
Administrative Contact
Joan X. Comella (Dr.)